Improved response with post-ASCT consolidation by low dose thalidomide, cyclophosphamide and dexamethasone as first line treatment for multiple myeloma

British Journal of Haematology

Volumn 158, Issue 4, 2012, Pages 499-505

  Rabin, Neil ^a   Percy, Laura ^b   Khan, Iftekhar ^b   Quinn, John ^b   D'Sa, Shirley ^a   Yong, Kwee L ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Clinical research; Consolidation; Myeloma therapy; Thalidomide

Indexed keywords

ACICLOVIR; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; IDARUBICIN; LAXATIVE; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ANEMIA; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER STAGING; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONSOLIDATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FATIGUE; FEMALE; HUMAN; INFECTION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE CRAMP; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84864302022     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2012.09188.x     Document Type: Article

References (28)

1. Attal, M., Harousseau, J.L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.J., Grosbois, B. & Bataille, R. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. New England Journal of Medicine, 349, 2495-2502.
2. Attal, M., Harousseau, J.L., Leyvraz, S., Doyen, C., Hulin, C., Benboubker, L., Yakoub Agha, I., Bourhis, J.H., Garderet, L., Pegourie, B., Dumontet, C., Renaud, M., Voillat, L., Berthou, C., Marit, G., Monconduit, M., Caillot, D., Grobois, B., Avet-Loiseau, H., Moreau, P. & Facon, T. (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood, 108, 3289-3294.
3. Attal, M., Olivier, P., Cances Lauwers, V. & Marit, G. (2011) Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignanciesd with the IFM 2005-02 trial. Haematologica, 96, S23.
4. Barlogie, B., Pineda-Roman, M., van Rhee, F., Haessler, J., Anaissie, E., Hollmig, K., Alsayed, Y., Waheed, S., Petty, N., Epstein, J., Shaughnessy, Jr, J.D., Tricot, G., Zangari, M., Zeldis, J., Barer, S. & Crowley, J. (2008a) Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood, 112, 3115-3121.
5. Barlogie, B., Shaughnessy, Jr, J.D. & Crowley, J. (2008b) Duration of survival in patients with myeloma treated with thalidomide. New England Journal of Medicine, 359, 210-212.
6. Benevolo, G., Larocca, A., Gentile, M., Pregno, P., Gay, F., Botto, B., Frairia, C., Evangelista, A., Morabito, F., Boccadoro, M., Vitolo, U. & Palumbo, A. (2011) The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. Cancer, 117, 1884-1890.
7. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. British Journal of Haematology, 102, 1115-1123.
8. Boyd, K.D., Ross, F.M., W.J., T. & Chiecchio, L. (2011) The clinical impact and molecular biology of del(17)p in multiple myeloma treated with conventional or thalidomide-based therapy. Genes, Chromosomes and Cancer, 50, 765-774.
9. Bruno, B., Rotta, M., Patriarca, F., Mordini, N., Allione, B., Carnevale-Schianca, F., Giaccone, L., Sorasio, R., Omede, P., Baldi, I., Bringhen, S., Massaia, M., Aglietta, M., Levis, A., Gallamini, A., Fanin, R., Palumbo, A., Storb, R., Ciccone, G. & Boccadoro, M. (2007) A comparison of allografting with autografting for newly diagnosed myeloma. New England Journal of Medicine, 356, 1110-1120.
10. Cavo, M., Tosi, P., Zamagni, E., Cellini, C., Tacchetti, P., Patriarca, F., Di Raimondo, F., Volpe, E., Ronconi, S., Cangini, D., Narni, F., Carubelli, A., Masini, L., Catalano, L., Fiacchini, M., de Vivo, A., Gozzetti, A., Lazzaro, A., Tura, S. & Baccarani, M. (2007) Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. Journal of Clinical Oncology, 25, 2434-2441.
11. Cavo, M., Tacchetti, P., Patriarca, F., Petrucci, M.T., Pantani, L., Galli, M., Di Raimondo, F., Crippa, C., Zamagni, E., Palumbo, A., Offidani, M., Corradini, P., Narni, F., Spadano, A., Pescosta, N., Deliliers, G.L., Ledda, A., Cellini, C., Caravita, T., Tosi, P. & Baccarani, M. (2010) Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet, 376, 2075-2085.
12. Chanan-Khan, A.A. & Giralt, S. (2010) Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. Journal of Clinical Oncology, 28, 2612-2624.
13. Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V.for the International Myeloma Working Group (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 1467-1473.
14. Garban, F., Attal, M., Michallet, M., Hulin, C., Bourhis, J.H., Yakoub-Agha, I., Lamy, T., Marit, G., Maloisel, F., Berthou, C., Dib, M., Caillot, D., Deprijck, B., Ketterer, N., Harousseau, J.L., Sotto, J.J. & Moreau, P. (2006) Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood, 107, 3474-3480.
15. Harousseau, J.L., Avet-Loiseau, H., Attal, M., Charbonnel, C., Garban, F., Hulin, C., Michallet, M., Facon, T., Garderet, L., Marit, G., Ketterer, N., Lamy, T., Voillat, L., Guilhot, F., Doyen, C., Mathiot, C. & Moreau, P. (2009) Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials. Journal of Clinical Oncology, 27, 5720-5726.
16. Kim, H.J., Yoon, S.S., Lee, D.S., Sohn, S.K., Eom, H.S., Lee, J.L., Chung, J.S., Kim, K., Suh, C., Won, J.H., Kim, J.S., Park, J.S., Kang, H.J., Seong, C.M., Kim, C.S., Lee, S.J. & Lee, J.H. (2012) Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Annals of Hematology, 91, 249-256.
17. Kyriakou, C., Thomson, K., D'Sa, S., Flory, A., Hanslip, J., Goldstone, A.H. & Yong, K.L. (2005) Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. British Journal of Haematology, 129, 763-770.
18. Lokhorst, H.M., van der Holt, B., Zweegman, S., Vellenga, E., Croockewit, S., van Oers, M.H., von dem Borne, P., Wijermans, P., Schaafsma, R., de Weerdt, O., Wittebol, S., Delforge, M., Berenschot, H., Bos, G.M., Jie, K.S., Sinnige, H., van Marwijk-Kooy, M., Joosten, P., Minnema, M.C., van Ammerlaan, R. & Sonneveld, P. (2011) A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood, 115, 1113-1120.
19. Mateos, M.V., Oriol, A., Martinez-Lopez, J., Gutierrez, N., Teruel, A.I., de Paz, R., Garcia-Larana, J., Bengoechea, E., Martin, A., Mediavilla, J.D., Palomera, L., de Arriba, F., Gonzalez, Y., Hernandez, J.M., Sureda, A., Bello, J.L., Bargay, J., Penalver, F.J., Ribera, J.M., Martin-Mateos, M.L., Garcia-Sanz, R., Cibeira, M.T., Ramos, M.L., Vidriales, M.B., Paiva, B., Montalban, M.A., Lahuerta, J.J., Blade, J. & Miguel, J.F. (2010) Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncology, 11, 934-941.
20. McCarthy, P., Owzar, K., Anderson, K. & Hofmeister, C. (2011) Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104. Haematologica, 96, S23.
21. Morgan, G.J., Gregory, W.M., Davies, F.E., Bell, S.E., Szubert, A.J., Brown, J.M., Coy, N.N., Cook, G., Russell, N.H., Rudin, C., Roddie, H., Drayson, M.T., Owen, R.G., Ross, F.M., Jackson, G.H. & Child, J.A. (2012) The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood, 119, 7-15.
22. Paiva, B., Vidriales, M.B., Cervero, J., Mateo, G., Perez, J.J., Montalban, M.A., Sureda, A., Montejano, L., Gutierrez, N.C., Garcia de Coca, A., de Las Heras, N., Mateos, M.V., Lopez-Berges, M.C., Garcia-Boyero, R., Galende, J., Hernandez, J., Palomera, L., Carrera, D., Martinez, R., de la Rubia, J., Martin, A., Blade, J., Lahuerta, J.J., Orfao, A. & San Miguel, J.F. (2008) Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood, 112, 4017-4023.
23. Palumbo, A., Bringhen, S., Rossi, D., Cavalli, M., Larocca, A., Ria, R., Offidani, M., Patriarca, F., Nozzoli, C., Guglielmelli, T., Benevolo, G., Callea, V., Baldini, L., Morabito, F., Grasso, M., Leonardi, G., Rizzo, M., Falcone, A.P., Gottardi, D., Montefusco, V., Musto, P., Petrucci, M.T., Ciccone, G. & Boccadoro, M. (2010) Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. Journal of Clinical Oncology, 28, 5101-5109.
24. Rosinol, L., Perez-Simon, J.A., Sureda, A., de la Rubia, J., de Arriba, F., Lahuerta, J.J., Gonzalez, J.D., Diaz-Mediavilla, J., Hernandez, B., Garcia-Frade, J., Carrera, D., Leon, A., Hernandez, M., Abellan, P.F., Bergua, J.M., San Miguel, J. & Blade, J. (2008) A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood, 112, 3591-3593.
25. Sonneveld, P., Scmidt-Wolf, I., van der Holt, B. & el Jarari, L. (2010) HOVON-65/GMMG-HD4 Randomised phase III trial comparing Bortezomib, Doxrubicin, Dexamethasone (PAD) vs VAD followed by high dose melphalan (HDM) and maintenance with bortezomib or thalidomide in patients with newly diagnosed multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 116, 40.
26. Spencer, A., Prince, H.M., Roberts, A.W., Prosser, I.W., Bradstock, K.F., Coyle, L., Gill, D.S., Horvath, N., Reynolds, J. & Kennedy, N. (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. Journal of Clinical Oncology, 27, 1788-1793.
27. van de Velde, H.J., Liu, X., Chen, G., Cakana, A., Deraedt, W. & Bayssas, M. (2007) Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica, 92, 1399-1406.
28. Zamagni, E., Patriarca, F., Nanni, C., Zannetti, B., Englaro, E., Pezzi, A., Tacchetti, P., Buttignol, S., Perrone, G., Brioli, A., Pantani, L., Terragna, C., Carobolante, F., Baccarani, M., Fanin, R., Fanti, S. & Cavo, M. (2011) Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation. Blood, 118, 5989-5995.